- EMR dividends total $2.22 annually, with a 1.40% forward yield near a $158.42 share price.
- A 48.6% payout ratio and $7.01 in free cash flow per share support Emerson’s dividend coverage.
- Shares trade near their 52-week high, making valuation and revenue growth key considerations for dividend investors.
Dividend Snapshot
Emerson Electric (NYSE: EMR) pays a $0.555 quarterly dividend, equal to $2.22 annually and a forward yield of about 1.40% at a share price near $158.42. Its next scheduled payment date is September 10, following the most recent May 15 ex-dividend date.
The company’s 48.6% payout ratio and 1.4% dividend yield suggest the EMR dividend is reasonably supported by earnings. With free cash flow per share near $7.01, Emerson has substantial room above its $2.22 annual dividend requirement.
Still, EMR is not a high-income stock. Its yield is below the roughly 1.89% five-year average yield, primarily because the share price has risen.
Dividend growth has also been uneven, with payment-based growth of about 4.0% over one year but only 1.7% annually over five years. Emerson dividends may therefore appeal more to investors seeking gradual growth than immediate income.
Earnings Support Dividend Coverage
Emerson delivered adjusted EPS of $1.71 against a $1.68 consensus and $4.87 billion of revenue, while maintaining fiscal 2026 EPS guidance of $6.55.
That modest beat supports dividend coverage and management’s financial outlook. However, revenue was essentially flat year over year, highlighting Emerson’s exposure to manufacturing activity, energy investment and industrial capital-spending cycles.
The long-term appeal lies in automation, control systems, measurement technology and industrial software. Stronger demand could support future EMR dividend increases, while softer orders would leave investors with less income cushion.
Institutions Add Shares
Institutional ownership stands at roughly 74.3%, with several investors disclosing new stakes. One investor reported a 4.29 million-share position valued near $613.8 million, while another disclosed 327,106 shares worth approximately $46.8 million.
These filings reflect past-quarter positions rather than real-time buying. Dividend investors should not treat 13F disclosures as immediate buy signals.
Valuation Limits Income Appeal
At roughly $158, EMR trades near its 52-week high of $165.15 and at about 34.7 times trailing earnings. The average analyst target near $167 implies limited near-term upside.
EMR suits investors seeking industrial quality and gradual dividend growth, rather than high current income. Revenue growth, fiscal 2026 guidance, free cash flow and the next dividend declaration remain key measures to watch.
